Hexarelin, also called examorelin, is a synthetic hexapeptide growth hormone secretagogue related to the GHRP family. Two characteristics separate it from its relatives: a documented interaction with a receptor in cardiac tissue, and a pronounced tendency toward desensitization with continued use.
This guide situates Hexarelin within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is hexarelin?
Hexarelin is a six-amino-acid synthetic peptide that activates the growth hormone secretagogue receptor GHS-R1a, stimulating pituitary growth hormone release. Structurally it sits close to GHRP-6, from which it was derived.
In acute administration it is a potent stimulus to growth hormone release — among the stronger of the GHRPs. The complication is what happens when acute becomes chronic.
Why the effect fades
Hexarelin shows marked desensitization: with repeated administration, the growth hormone response to a given dose declines substantially. Studies have documented this attenuation developing over a matter of weeks of continuous use.
The mechanism is receptor-level. Sustained agonism at GHS-R1a leads to receptor downregulation and reduced responsiveness, the same phenomenon that limits many receptor-targeted drugs. Hexarelin appears to be particularly susceptible.
The clinical implication is significant and frequently overlooked: an agent that produces an impressive acute response is not necessarily an agent that produces a sustained one. Anyone evaluating a secretagogue on the strength of a single-dose growth hormone spike is measuring the wrong thing. This same principle underlies why pulsatile physiologic signaling is generally preferred over continuous stimulation across the whole axis.
The CD36 and cardiac findings
Hexarelin binds CD36, a scavenger receptor expressed in cardiac tissue, independently of its action at the growth hormone secretagogue receptor. Preclinical work has explored cardioprotective effects in models of ischemia and cardiac dysfunction, and some effects appear to occur independently of growth hormone release.
This is genuinely interesting pharmacology and it is also where careful reading is required. These findings are largely preclinical and mechanistic. They do not constitute evidence that hexarelin treats or prevents cardiac disease in humans, and they should never be presented to a patient as though they do. A receptor interaction observed in a laboratory model is a research finding, not a clinical indication.
Regulatory status
Hexarelin is not an FDA-approved drug. Its status with respect to pharmacy compounding falls into the category requiring direct verification rather than assumption — a designation that covers a substantial portion of this formulary and that has changed repeatedly since 2023.
Material sold under this name online is a research chemical outside the regulated supply. Our peptide formulary carries a current status tag for every agent, and verifying at the time of the conversation is the only reliable approach in this category.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering growth hormone axis biology, receptor desensitization, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →